http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 22 Oct 2024 15:02:12 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/POINT+Biopharma+Global+Inc.+%28PNT%29+PT+Raised+to+%24105+at+CFRA/23864435.html <p>CFRA analyst Jonathan Sakraida raised the price target on POINT Biopharma Global Inc. (NASDAQ: PNT) to $105.00 (from $100.00) while maintaining a Hold rating.</p><p>The analyst comments "Following PNR's Q3 print, we adjust our 12-month target to $105 from $100, valuing shares at 21.8x our 2025 EPS view of $4.80 (in line with the previous forecast; 2024 lifted by $0.02 to $4.27), above PNR's historical average. We believe a higher multiple is warranted as PNR successfully diversifies its portfolio beyond its short-cycle pools business, helping to smooth out earnings and sales growth. PNR's Q3 EPS of $1.09 (up 16% Y/Y) beat http://www.streetinsider.com/Analyst+PT+Change/POINT+Biopharma+Global+Inc.+%28PNT%29+PT+Raised+to+%24105+at+CFRA/23864435.html Tue, 22 Oct 2024 15:02:12 -0400 PNT http://www.streetinsider.com/Analyst+Comments/POINT+Biopharma+Global+Inc.+%28PNT%29+PT+Raised+to+%24105+at+CFRA/23864435.html <p>CFRA analyst Jonathan Sakraida raised the price target on POINT Biopharma Global Inc. (NASDAQ: PNT) to $105.00 (from $100.00) while maintaining a Hold rating.</p><p>The analyst comments "Following PNR's Q3 print, we adjust our 12-month target to $105 from $100, valuing shares at 21.8x our 2025 EPS view of $4.80 (in line with the previous forecast; 2024 lifted by $0.02 to $4.27), above PNR's historical average. We believe a higher multiple is warranted as PNR successfully diversifies its portfolio beyond its short-cycle pools business, helping to smooth out earnings and sales growth. PNR's Q3 EPS of $1.09 (up 16% Y/Y) beat http://www.streetinsider.com/Analyst+Comments/POINT+Biopharma+Global+Inc.+%28PNT%29+PT+Raised+to+%24105+at+CFRA/23864435.html Tue, 22 Oct 2024 15:02:12 -0400 PNT http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Board+Changes/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html <p>Delcath Systems, Inc. (Nasdaq: DCTH) is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024.</p><p>“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving patient outcomes.”</p><p>Dr. Martell is currently an independent director at the publicly traded http://www.streetinsider.com/Corporate+News/Delcath+Systems+%28DCTH%29+Appoints+Bridget+Martell+to+its+Board/23282414.html Tue, 28 May 2024 09:30:42 -0400 ACHV ALGS DCTH PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html <p> NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of Directors effective May 23, 2024. </p><p> “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell’s extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be http://www.streetinsider.com/Press+Releases/Delcath+Systems+Announces+Appointment+of+Bridget+Martell%2C+MA%2C+MD+to+Delcath%E2%80%99s+Board+of+Directors/23282349.html Tue, 28 May 2024 09:30:00 -0400 A.00641573 A.35808027 A.40557829 A.50114142 A.50114193 ACHV ALGS DCTH O.00039076 O.00644671 O.02027210 O.02931219 O.21657093 O.47615966 O.48073339 O.48989253 PNT